Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 51332
Gene Symbol: SPTBN5
SPTBN5
0.100 GeneticVariation disease GWASCAT A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. 31241743 2019
Entrez Id: 9398
Gene Symbol: CD101
CD101
0.040 Biomarker disease BEFREE Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. 29555631 2018
Entrez Id: 9398
Gene Symbol: CD101
CD101
0.040 Biomarker disease BEFREE CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. 29133552 2018
Entrez Id: 9398
Gene Symbol: CD101
CD101
0.040 Biomarker disease BEFREE CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. 27919901 2017
Entrez Id: 9398
Gene Symbol: CD101
CD101
0.040 Biomarker disease BEFREE CD101, a novel echinocandin with a long plasma half-life and enhanced stability, is in development for once-weekly IV administration for the treatment of candidemia and invasive candidiasis. 28826987 2017
Entrez Id: 64581
Gene Symbol: CLEC7A
CLEC7A
0.030 Biomarker disease BEFREE Whereas the dectin-1/CARD9 signaling pathway is nonredundant in mucosal immunity to C. albicans, a partial deficiency of β-glucan recognition has a minor impact on susceptibility to candidemia. 21881131 2011
Entrez Id: 64581
Gene Symbol: CLEC7A
CLEC7A
0.030 GeneticVariation disease BEFREE The role of Candida species herein has recently been rediscovered since a 'loss-of-function' Y238X polymorphism in dectin-1, a C-type lectin receptor recognizing the β-1,3-glucan motif of Candida, resulted in diminished membrane expression and lower cytokine responses upon β-1,3-glucan recognition, and was associated with increased Candida colonization of SCT recipients, rendering them at risk for candidaemia. 21178438 2011
Entrez Id: 64581
Gene Symbol: CLEC7A
CLEC7A
0.030 GeneticVariation disease BEFREE Screening for the DECTIN-1 Y238X polymorphism within a group of 142 patients undergoing HSCT was correlated with Candida colonization and candidemia. 19614557 2009
Entrez Id: 64170
Gene Symbol: CARD9
CARD9
0.020 AlteredExpression disease BEFREE Thus, Dok3 suppresses Card9 signaling, and disrupting Dok3-Card9 interaction or inhibiting PP1 activity represents therapeutic opportunities to develop drugs to combat candidaemia. 31180338 2019
Entrez Id: 8864
Gene Symbol: PER2
PER2
0.020 Biomarker disease BEFREE The proportion of patients receiving treatment increased (65.5%, 79.4% and 74.7% in periods 1, 2 and 3, respectively, p = 0.04), and the median time from candidemia to treatment initiation decreased from 4 days in period 1 (range 0-32 days) to 2 days in period 2 (range 0-33 days) and 2 days in period 3 (range 0-14 days, p < 0.001). 30118654 2018
Entrez Id: 8864
Gene Symbol: PER2
PER2
0.020 Biomarker disease BEFREE The study period was split into two periods, 2007 to 2010 (period 1) and 2011 to 2014 (period 2).The number of episodes of <i>C. albicans</i> and <i>C. parapsilosis</i> candidemia (<i>n</i> = 262 versus <i>n</i> = 170, respectively), the mean incidence (1.62 versus 1.36 episodes per 1,000 admissions, respectively), and the percentage of episodes caused by clusters (overall clusters [40% versus 12%] and tracking clusters [18% versus 3%], respectively) were significantly lower in period 2 than in period 1. 29743306 2018
Entrez Id: 3586
Gene Symbol: IL10
IL10
0.020 GeneticVariation disease BEFREE In the multivariable model, persistent candidemia was significantly associated with (odds ratio [95% confidence interval]): total parenteral nutrition (2.79 [1.26-6.17]), dialysis dependence (3.76 [1.46-8.64]), and the SNPs IL10 rs1800896 (3.45 [1.33-8.93]) and IL12B rs41292470 (5.36 [1.51-19.0]). 22144535 2012
Entrez Id: 64170
Gene Symbol: CARD9
CARD9
0.020 GeneticVariation disease BEFREE No significant association between the single-nucleotide polymorphisms DECTIN-1 Y238X and CARD9 S12N and the prevalence of candidemia was found, despite the association of the DECTIN-1 238X allele with impaired in vitro and in vivo cytokine production. 21881131 2011
Entrez Id: 3586
Gene Symbol: IL10
IL10
0.020 GeneticVariation disease BEFREE IL-10 production was higher in C. albicans-stimulated PBMC from volunteers bearing the TLR4 Asp299Gly polymorphism, and a similar tendency was observed in TLR4 Asp299Gly heterozygous patients who had recovered from candidemia. 16613760 2006
Entrez Id: 79930
Gene Symbol: DOK3
DOK3
0.010 AlteredExpression disease BEFREE Thus, Dok3 suppresses Card9 signaling, and disrupting Dok3-Card9 interaction or inhibiting PP1 activity represents therapeutic opportunities to develop drugs to combat candidaemia. 31180338 2019
Entrez Id: 4680
Gene Symbol: CEACAM6
CEACAM6
0.010 Biomarker disease BEFREE Candidemia following NCA in neonates (p = 0.02), infants (p = 0.04) and adults (p = 0.02) in ICU and immunocompromised patients were significantly higher. 31226938 2019
Entrez Id: 3732
Gene Symbol: CD82
CD82
0.010 GeneticVariation disease BEFREE CD82 knockout mice were more susceptible to <i>C. albicans</i> as compared with wild-type mice.Furthermore, patient <i>C. albicans</i>-induced cytokine production was influenced by two human CD82 single nucleotide polymorphisms, whereas an additional CD82 single nucleotide polymorphism increased the risk for candidemia independent of cytokine production. 31010852 2019
Entrez Id: 4846
Gene Symbol: NOS3
NOS3
0.010 Biomarker disease BEFREE Compared to wild type mice, Nos3-/- mice showed significantly higher survival of candidemia caused by Candida albicans SC5314. 31671151 2019
Entrez Id: 100137049
Gene Symbol: PLA2G4B
PLA2G4B
0.010 GeneticVariation disease BEFREE We observed strong association between candidemia and a variant, rs8028958, that significantly affects the expression levels of PLA2G4B in blood. 31241743 2019
Entrez Id: 1089
Gene Symbol: CEACAM4
CEACAM4
0.010 Biomarker disease BEFREE Candidemia following NCA in neonates (p = 0.02), infants (p = 0.04) and adults (p = 0.02) in ICU and immunocompromised patients were significantly higher. 31226938 2019
Entrez Id: 10563
Gene Symbol: CXCL13
CXCL13
0.010 Biomarker disease BEFREE In conclusion, our results indicated that CXCL13 had strong potential as a novel biomarker of diagnosis and prognosis for candidemia. 29198822 2018
Entrez Id: 796
Gene Symbol: CALCA
CALCA
0.010 AlteredExpression disease BEFREE Moreover, we observed that high PCT and BDG levels as well as low PLT counts were also associated with mortality from candidemia. 30030692 2018
Entrez Id: 7389
Gene Symbol: UROD
UROD
0.010 AlteredExpression disease BEFREE Moreover, we observed that high PCT and BDG levels as well as low PLT counts were also associated with mortality from candidemia. 30030692 2018
Entrez Id: 284697
Gene Symbol: BTBD8
BTBD8
0.010 GeneticVariation disease BEFREE Based on logistic regression modelling, admission to north Indian ICUs [OR 2.1 (1.2-3.8); P  =   0.012], public-sector hospital [OR 2.2 (1.2-3.9); P  =   0.006], underlying respiratory illness [OR 2.1 (1.3-3.6); P  =   0.002], vascular surgery [OR 2.3 (1.00-5.36); P  =   0.048], prior antifungal exposure [OR 2.8 (1.6-4.8); P  <   0.001] and low APACHE II score [OR 0.8 (0.8-0.9); P  =   0.007] were significantly associated with C. auris candidaemia. 28333181 2017
Entrez Id: 11331
Gene Symbol: PHB2
PHB2
0.010 GeneticVariation disease BEFREE ICU-acquired candidaemia in France: Epidemiology and temporal trends, 2004-2013 - A study from the REA-RAISIN network. 28366686 2017